Targeting KRas-dependent tumor growth, circulating tumor cells and metastasis in vivo by clinically significant miR-193a-3p

KRas is mutated in a significant number of human cancers and so there is an urgent therapeutic need to target KRas signaling. To target KRas in lung cancers we used a systems approach of integrating a genome-wide miRNA screen with patient-derived phospho-proteomic signatures of the KRas downstream p...

Descripción completa

Detalles Bibliográficos
Autores principales: Seviour, Elena G., Sehgal, Vasudha, Mishra, Dhruva, Rupaimoole, Rajesha, Rodriguez-Aguayo, Cristian, Lopez-Berestein, Gabriel, Lee, Ju-Seog, Sood, Anil K., Kim, Min P., Mills, Gordon B., Ram, Prahlad T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344721/
https://www.ncbi.nlm.nih.gov/pubmed/27669434
http://dx.doi.org/10.1038/onc.2016.308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344721/
https://www.ncbi.nlm.nih.gov/pubmed/27669434
http://dx.doi.org/10.1038/onc.2016.308

Ejemplares similares